Table 1.
Clinical and pathologic characteristics of grade 1 and 2 endometrioid and Grade 3 endometrioid, serous, and clear cell stage IIIC endometrial cancers.
| Characteristic | G1/2EC (n = 48) |
G3EC (n = 61) |
P value |
|---|---|---|---|
| Age at surgery, mean (SD), y | 66.2 (14.3) | 64.7 (10.4) | .51 |
| FIGO grade, no. (%) | <.001 | ||
| 1 | 15 (31.3) | … | |
| 2 | 33 (68.8) | … | |
| 3 | … | 61 (100.0) | |
| Histology, no. (%) | <.001 | ||
| Endometrioid | 48 (100.0) | 23 (37.7) | |
| Nonendometrioid | … | 38 (62.3) | |
| Lymphovascular space invasion, no. (%) | 13 (27.1) | 36 (59.0) | <.001 |
| Myometrial invasion >50%, no. (%) | 28 (58.3) | 43 (70.5) | .19 |
| Primary tumor diameter >2 cm, no. (%) | 47 (97.9) | 55/59 (93.2) | .25 |
| Cervical stromal invasion, no. (%) | 7 (14.6) | 14 (23.0) | .27 |
| Stage, no. (%)a | .21 | ||
| IIICo | 27 (56.3) | 27 (44.3) | |
| IIICab | 21 (43.8) | 34 (55.7) | |
| Site of node positivity, no. (%) | .90 | ||
| Pelvis only | 23 (47.9) | 30 (49.2) | |
| Paraaortic ± pelvis | 25 (52.1) | 31 (50.8) | |
| Positivity in ≥3 nodes, no. (%) | 21 (43.8) | 30/60 (50.0) | .52 |
| Positive lymph node ratio >0.10, no. (%) | 14 (29.2) | 26/60 (43.3) | .13 |
| Extent of lymphadenectomy, no. (%)b | .80 | ||
| Anything less than systematic | 7 (14.6) | 10 (16.4) | |
| Systematic | 41 (85.4) | 51 (83.6) | |
| Adjuvant chemotherapy, no. (%) | 18/46 (39.1) | 34/57 (59.6) | .04 |
| Adjuvant EBRT, no. (%) | 28/45 (62.2) | 29/58 (50.0) | .22 |
Abbreviations: EBRT, external beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics; G1/2EC, FIGO grade 1 and 2 endometrioid endometrial carcinoma; G3EC, FIGO grade 3 endometrial carcinoma.
a
Stage: IIICo, positive node(s) only; IIICab, positive node(s) and adnexal involvement, uterine serosal involvement, vaginal involvement, and/or positive peritoneal cytology.
b
Systematic was defined as ≥10 pelvic and ≥5 paraaortic lymph nodes removed and histologically assessed.